|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Research progress on microstructure evolution of semi-solid aluminum alloys in ultrasonic field and their rheocasting显示文摘The effects of ultrasonic vibration(UV)treatment on microstructure of semi-solid aluminum alloys and the application of UV in rheocasting process are reviewed.Good semi-solid slurry can be produced by high-intensity UV process for aluminum alloys.The microstructures of Al-Si,Al-Mg and Al-Cu alloys produced by rheocasting assisted with UV are compact and with fine grains.The mechanical properties of the UV treated alloys are increased by about 20%-30%.Grain refinement of the alloys is generally considered because of cavitation and acoustic streaming caused by UV.Apart from these mechanisms,a hypothesis of the fuse of dendrite root caused by capillary infiltration in the ultrasonic field,as well as a mechanism of crystallites falling off from the mould-wall and crystal multiplication by mechanical vibration effect in indirect ultrasonic vibration are proposed to explain the microstructure evolution of the alloys. | Wu Shusen Lin Chong Lü Shulin Sha Meng | 2014 | China Foundry2014，11，4： | 7 |
| 2 | Combined effects of ultrasonic vibration and manganese on Fe-containing inter-metallic compounds and mechanical properties of Al-17Si alloy with 3wt.%Fe显示文摘The research studied the combined effects of ultrasonic vibration (USV) and manganese on the Fe-containing inter-metallic compounds and mechanical properties of Al-17Si-3Fe-2Cu-1Ni (wt.%) alloys. The results showed that, without USV, the alloys with 0.4wt.% Mn or 0.8wt.% Mn both contain a large amount of coarse plate-like δ-Al4(Fe,Mn)Si2 phase and long needle-like β-Al5(Fe,Mn)Si phase. When the Mn content changes from 0.4wt.% to 0.8wt.% in the alloys, the amount and the length of needle-like β-Al5(Fe,Mn)Si phase decrease and the plate-like δ-Al4(Fe,Mn)Si2 phase becomes much coarser. After USV treatment, the Fe-containing compounds in the alloys are refined and exist mainly as δ-Al4(Fe,Mn)Si2 particles with an average grain size of about 20 μm, and only a small amount of β-Al5(Fe,Mn)Si phase remains. With USV treatment, the ultimate tensile strengths (UTS) of the alloys containing 0.4wt.%Mn and 0.8wt.%Mn at room temperature are 253 MPa and 262 MPa, respectively, and the ultimate tensile strengths at 350 °C are 129 MPa and 135 MPa, respectively. It is considered that the modified morphology and uniform distribution of the Fe-containing inter-metallic compounds, which are caused by the USV process, are the main reasons for the increase in the tensile strength of these two alloys. | Lin Chong Wu Shusen Zeng Jinbiao An Ping Wan Li | 2013 | China Foundry2013，10，3： | 6 |
| 3 | Structural shifts in the intestinal microbiota of rats treated with cyclosporine A after orthotropic liver transplantation显示文摘Understanding the effect of immunosuppressive agents on intestinal microbiota is important to reduce the mortality and morbidity from orthotopic liver transplantation (OLT). We investigated the relationship between the commonly used immunosuppressive agent cyclosporine A (CSA) and the intestinal microbial variation in an OLT model. The rat samples were divided as follows:(1) N group (normal control);(2) I group (isograft LT, Brown Norway [BN] rat to BN);(3) R group (allograft LT, Lewis to BN rat);and (4) CSA group (R group treated with CSA). The intestinal microbiota was assayed by denaturing gradient gel electrophoresis profiles and by using real-time polymerase chain reaction. The liver histopathology and the alanine/aspartate aminotransferase ratio after LT were both ameliorated by CSA. In the CSA group, the numbers of rDNA gene copies of Clostridium cluster I, Clostridium cluster XIV, and Enterobacteriaceae decreased, whereas those of Faecalibacterium prausnitzii increased compared with the R group. Cluster analysis indicated that the samples from the N, I, and CSA groups were clustered, whereas the other clusters contained the samples from the R group. Hence, CSA ameliorates hepatic graft injury and partially restores gut microbiota following LT, and these may benefit hepatic graft rejection. | Junjun Jia Xinyao Tian Jianwen Jiang Zhigang Ren Haifeng Lu Ning He Haiyang Xie Lin Zhou Shusen Zheng | 2019 | Frontiers of Medicine2019，13，4： | 5 |
| 4 | Severity of early allograft dysfunction following donation after circulatory death liver transplantation:a multicentre study显示文摘Background:Early allograft dysfunction(EAD)is associated with decreased graft and patient survival rates.This study aimed to identify the severity of EAD and develop a predictive model for EAD after donation after circulatory death(DCD)liver transplantation(LT).Furthermore,the influence of operative time on EAD incidence was also evaluated.Methods:In this retrospective,multicentre cohort study,nomograms were established based on a single-centre training cohort(n=321)and validated in a 3-center validation cohort(n=501).Results:The incidence rate of EAD was 46.4%(149/321)in the training cohort and 40.5%(203/501)in the validation cohort.Of the 149 EAD patients in the training cohort,77 patients with either elevated alanine aminotransferase(ALT)or aspartate aminotransferase(AST)were classified as having EAD type A,and the rest of the EAD patients were classified as having EAD type B.Recipients with EAD type B had lower graft and patient survival rates than recipients with EAD type A(P=0.043 and 0.044,respectively).We further developed a nomogram to predict EAD(graft weight,cold ischemia time,donor age,model for end-stage liver disease(MELD)score)and another nomogram to predict EAD type B(graft weight,cold ischemia time,MELD score).The nomograms for the prediction of EAD and EAD type B had good discrimination[concordance index(C-index)=0.712(0.666-0.758),0.707(0.641-0.773)]and calibration[Hosmer-Lemeshow(HL)P=0.384,P=0.425]in the validation cohort.An increased operative time(>6 h)was associated with increased EAD and EAD type B incidence in the high-risk group(P=0.005,P=0.020,respectively).Conclusions:EAD type B was associated with decreased graft and patient survival rates.The novel nomograms effectively predicted the incidence of EAD and EAD type B in DCD LT patients. | Kun Wang Di Lu Yuhui Liu Wangyao Li Li Zhuang Zhenyu Ma Qinfen Xie Binhua Pan Yichao Wu Junli Chen Lidan Lin Xiaowen Feng Qiang Wei Xuyong Wei Haiyang Xie Zhengxin Wang Shusen Zheng Xiao Xu | 2021 | Hepatobiliary Surgery and Nutrition2021，10，1： | 4 |
| 5 | Involvement of Th17 and Th1 Effector Responses in Patients with Hepatitis B显示文摘 | Yufu Ye Xiaojun Xie Jiwei Yu Lin Zhou Haiyang Xie Guoping Jiang Xiaobo Yu Wenjin Zhang Jian Wu Shusen Zheng | 2010 | Journal of Clinical Immunology2010，，4： | 3 |
| 6 | Assessing Donor Liver Quality and Restoring Graft Function in the Era of Extended Criteria Donors显示文摘Liver transplantation(LT)is the final treatment option for patients with end-stage liver disease.The increasing donor shortage results in the wide usage of grafts from extended criteria donors across the world.Using such grafts is associated with the elevated incidences of post-transplant complications including initial nonfunction and ischemic biliary tract diseases,which significantly reduce recipient survival.Although several clinical factors have been demonstrated to impact donor liver quality,accurate,comprehensive,and effective assessment systems to guide decision-making for organ usage,restoration or discard are lacking.In addition,the development of biochemical technologies and bioinformatic analysis in recent years helps us better understand graft injury during the perioperative period and find potential ways to restore graft function.Moreover,such advances reveal the molecular profiles of grafts or perfusate that are susceptible to poor graft function and provide insight into finding novel biomarkers for graft quality assessment.Focusing on donors and grafts,we updated potential biomarkers in donor blood,liver tissue,or perfusates that predict graft quality following LT,and summarized strategies for restoring graft function in the era of extended criteria donors.In this review,we also discuss the advantages and drawbacks of these potential biomarkers and offer suggestions for future research. | Yimou Lin Haitao Huang Lifeng Chen Ruihan Chen Jimin Liu Shusen Zheng Qi Ling | 2023 | Journal of Clinical and Translational Hepatology2023，11，1： | 2 |
| 7 | Clear mortality gap caused by graft macrosteatosis in Chinese patients after cadaveric liver transplantation显示文摘Background:Liver transplantation(LT)is one of the most effective surgical treatment for patients with end-stage liver disease.Steatosis is a contributor for inferior graft quality.But its impact and safety on transplantation was less assessed in Chinese patients.Methods:Graft steatosis and related information involved in recipients,donors and surgical procedures were retrospectively collected from 239 patients.Results:Donor macrosteatosis(MaS)caused about 2.14 and 2.80 folds of increment on patient and graft mortality.Dose-response analysis revealed prominent risk of grafts on overall patient/organ mortality when MaS content exceeded 10%(P<0.05).Noteworthy,deaths were only observed in MaS group when concurrent with extremely higher post-transplant alanine aminotransferase(ALT,64%).However,microsteatosis(MiS)grafts didn’t affect outcomes after LT.In a cohort of Chinese patients,MaS had comprehensive effects on post-transplant outcomes with relatively lower safety threshold at 10%.Mortality gap caused by MaS grafts was observed in patients with severer ischemia reperfusion injury.Conclusions:Our study revealled the graft MaS affected the post-transplant outcomes in lower risk cutoff in Chinese patients.Further study is worthy to validate these results and investigate inner mechanism under the phenomenon. | Zhengtao Liu Wenchao Wang Li Zhuang Jingfeng Liu Shuping Que Dan Zhu Linfang Dong Jian Yu Lin Zhou Shusen Zheng | 2020 | Hepatobiliary Surgery and Nutrition2020，9，6： | 2 |
| 8 | Preparation and rheocasting of semisolid slurry of 5083 Al alloy with indirect ultrasonic vibration process显示文摘 | Shulin Lü Shusen Wu Chong Lin Zuqi Hu Ping An | 2011 | Materials Science & Engineering A2011，，29： | 2 |
| 9 | Biomarkers of aging显示文摘Aging biomarkers are a combination of biological parameters to(i)assess age-related changes,(ii)track the physiological aging process,and(iii)predict the transition into a pathological status.Although a broad spectrum of aging biomarkers has been developed,their potential uses and limitations remain poorly characterized.An immediate goal of biomarkers is to help us answer the following three fundamental questions in aging research:How old are we?Why do we get old?And how can we age slower?This review aims to address this need.Here,we summarize our current knowledge of biomarkers developed for cellular,organ,and organismal levels of aging,comprising six pillars:physiological characteristics,medical imaging,histological features,cellular alterations,molecular changes,and secretory factors.To fulfill all these requisites,we propose that aging biomarkers should qualify for being specific,systemic,and clinically relevant. | Aging Biomarker Consortium Hainan Bao Jiani Cao Mengting Chen Min Chen Wei Chen Xiao Chen Yanhao Chen Yu Chen Yutian Chen Zhiyang Chen Jagadish K Chhetri Yingjie Ding Junlin Feng Jun Guo Mengmeng Guo Chuting He Yujuan Jia Haiping Jiang Ying Jing Dingfeng Li Jiaming Li Jingyi Li Qinhao Liang Rui Liang Feng Liu Xiaoqian Liu Zuojun Liu Oscar Junhong Luo Jianwei Lv Jingyi Ma Kehang Mao Jiawei Nie Xinhua Qiao Xinpei Sun Xiaoqiang Tang Jianfang Wang Qiaoran Wang Siyuan Wang Xuan Wang Yaning Wang Yuhan Wang Rimo Wu Kai Xia Fu-Hui Xiao Lingyan Xu Yingying Xu Haoteng Yan Liang Yang Ruici Yang Yuanxin Yang Yilin Ying Le Zhang Weiwei Zhang Wenwan Zhang Xing Zhang Zhuo Zhang Min Zhou Rui Zhou Qingchen Zhu Zhengmao Zhu Feng Cao Zhongwei Cao Piu Chan Chang Chen Guobing Chen Hou-Zao Chen Jun Chen Weimin Ci Bi-Sen Ding Qiurong Ding Feng Gao Jing-Dong JHan Kai Huang Zhenyu Ju Qing-Peng Kong Ji Li Jian Li Xin Li Baohua Liu Feng Liu Lin Liu Qiang Liu Qiang Liu Xingguo Liu Yong Liu Xianghang Luo Shuai Ma Xinran Ma Zhiyong Mao Jing Nie Yaojin Peng Jing Qu Jie Ren Ruibao Ren Moshi Song Zhou Songyang Yi Eve Sun Yu Sun Mei Tian Shusen Wang Si Wang Xia Wang Xiaoning Wang Yan-Jiang Wang Yunfang Wang Catherine CL Wong Andy Peng Xiang Yichuan Xiao Zhengwei Xie Daichao Xu Jing Ye Rui Yue Cuntai Zhang Hongbo Zhang Liang Zhang Weiqi Zhang Yong Zhang Yun-Wu Zhang Zhuohua Zhang Tongbiao Zhao Yuzheng Zhao Dahai Zhu Weiguo Zou Gang Pei Guang-Hui Liu | 2023 | Science China(Life Sciences)2023，66，5： | 2 |
| 10 | Development of double-cantilever infrared detectors:Fabrication,curvature control and demonstration of thermal detection显示文摘 | Shusen Huang Hu Tao I-Kuan Lin Xin Zhang | 2008 | Sensors and Actuators2008，，： | 1 |
| 11 | A pathogenic role of IL- 17 at the early stage of corneal allograft rejection显示文摘 | Haiyong Chen Weilin Wang Haiyang Xie Xiao Xu Jian Wu Zhijun Jiang Mangli Zhang Lin Zhou Shusen Zheng | 2009 | Transplant Immunology2009，，3： | 1 |
| 12 | Extracellular matrix and its therapeutic potential for cancer treatment显示文摘The extracellular matrix(ECM)Is one of the major components of tumors that plays multiple crucial roles,including mechanical support,modulation of the microenvironment,and a source of signaling molecules.The quantity and cross-linking status of ECM components are major factors determining tissue stiffness.During tumorigenesis,the interplay between cancer cells and the tumor microenvironment(TME)often results in the stiffness of the ECM,leading to aberrant mechanotransduction and further malignant transformation.Therefore,a comprehensive understanding of ECM dysregulation in the TME would contribute to the discovery of promising therapeutic targets for cancer treatment.Herein,we summarized the knowledge concerning the following:(1)major ECM constituents and their functions in both normal and malignant conditions;(2)the interplay between cancer cells and the ECM in the TME;(3)key receptors for mechanotransduction and their alteration during carcinogenesis;and(4)the current therapeutic strategies targeting aberrant ECM for cancer treatment. | Jiacheng Huang Lele Zhang Dalong Wan Lin Zhou Shusen Zheng Shengzhang Lin Yiting Qiao | 2021 | Signal Transduction and Targeted Therapy2021，6，5： | 1 |
| 13 | Mitofusin-2 is a novel direct target of p53显示文摘 | Weilin Wang Xiaofei Cheng Jianju Lu Jianfeng Wei Guanghou Fu Feng Zhu Changku Jia Lin Zhou Haiyang Xie Shusen Zheng | 2010 | Biochemical and Biophysical Research Communications2010，，4： | 1 |
| 14 | Hepatitis B virus X protein inhibits p53-mediated upregulation of mitofusin-2 in hepatocellular carcinoma cells显示文摘 | Weilin Wang Dongkai Zhou Jianfeng Wei Zehui Wu Xiaofei Cheng Qiang Sun Haiyang Xie Lin Zhou Shusen Zheng | 2012 | Biochemical and Biophysical Research Communications2012，，2： | 1 |
| 15 | Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells显示文摘 | Weilin Wang Jianju Lu Feng Zhu Jianfeng Wei Changku Jia Yuanbiao Zhang Lin Zhou Haiyang Xie Shusen Zheng | 2012 | Medical Oncology2012，，1： | 1 |
| 16 | Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma显示文摘 | Baiye Jin Guanghou Fu Hao Pan Xiaofei Cheng Lin Zhou Jia Lv Geming Chen Shusen Zheng | 2011 | Medical Oncology2011，，1： | 1 |
| 17 | Pro-apoptotic and anti-proliferative effects of mitofusin-2 via Bax signaling in hepatocellular carcinoma cells显示文摘 | Weilin Wang Jianju Lu Feng Zhu Jianfeng Wei Changku Jia Yuanbiao Zhang Lin Zhou Haiyang Xie Shusen Zheng | 2012 | Medical Oncology2012，，1： | 1 |
| 18 | Involvement of Th17 and Th1 Effector Responses in Patients with Hepatitis B显示文摘 | Yufu Ye Xiaojun Xie Jiwei Yu Lin Zhou Haiyang Xie Guoping Jiang Xiaobo Yu Wenjin Zhang Jian Wu Shusen Zheng | 2010 | Journal of Clinical Immunology2010，，4： | 1 |
| 19 | MHC-mismatched mice liver transplantation promotes tumor growth in liver graft显示文摘 | Sheng Yan Yuan Ding Yang Tian Zhongjie Lu Yan Wang Qiyi Zhang Yufu Ye Lin Zhou Haiyang Xie Hui Chen Minghao Zheng Shusen Zheng | 2014 | Cancer Letters2014，，： | 1 |
| 20 | Preliminary outcome of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin’s lymphoma: single institution experience显示文摘Objective: The prognosis of relapsed or refractory B-cell lymphoma is poor, with a short-term survival after conven- tional second-line chemotherapy. Rituximab, a chimeric anti-CD20 antigen, in combination with CHOP or CHOP-like chemo- therapy may improve both disease free survival (DFS) and overall survival (OS) of naive patients, but its role in the second-line therapy for relapsed non-Hodgkin’s Lymphoma (NHL) remains to be defined. This study aimed to evaluate the efficacy of rituximab-containing salvage regimens for relapsed or refractory NHL, and observe the toxicities. Methods: The clinical data of 54 patients, who were with relapsed or refractory NHL and treated in the Cancer Center of Sun Yat-sen University, were analyzed retrospectively. Of the 54 patients, 29 were man, 25 were women, with a median age of 52.5 years old (range 18 to 75); 50 patients (92.6%) scored 0–1 for the ECOG performance status; for second-line international prognostic index (sIPI), 21 (38.9%) scored 0–1, 30 (55.6%) scored 2 to 3, and 3 (5.6%) scored 4–5; 40 cases were diffuse large B-cell lymphoma (DLBCL), accounting for 74.1% of all subtypes. Rituximab was administered intravenously at a dose of 375 mg/m2 at the day before each chemotherapy cycle. The second or third-line salvage regimens included EPOCH, CHOP, DHAP, DICE, IVAC, IMVP-16 and FND. Results: Of the 54 patients, 49 received retuximab-containing salvage regimens. The objective response rate of the 45 evaluable cases was 68.8%, with a complete remission (CR) rate of 37.7%; 3 patients achieved CR after radiotherapy follow- ing rituximab-based regimens and 3 achieved CR after autologous hematopoietic stem cell transplantation. The most frequent adverse events were leucopenia, nausea and alopecia. The addition of rituximab to chemotherapy only elevated the occurrence of mild infusion-related reactions, such as chills, fever and pruritus. The median follow-up time was 18 months (range 2–86 months); 5 patients were lost, 24 were dead (23 died of lymphoma, and 1 died of severe hepatitis), the other patients remained alive. The median survival time was 32 months (range 2–86 months, 95% confidential interval 16–48 months). The 1-, 2- and 3-year OS rates were 70.6%, 53.6% and 41.5%, respectively. The median TTP was 6 months (range 0–52 months). The median PFS was 10 months (range 0–47 months, 95% CI 0–26 months). The 1- and 2-year PFS were 49.3% and 41.3%. Conclusion: Rituximab-containing salvage regimens are effective and well tolerated therapy for patients with relapsed or refractory B-cell NHL, even those were extensively treated. | Bufei Wang Huiqiang Huang Qjng Bu Zhongjun Xia Xubin Lin Fenghua Wang Yuhong Li Yulong Peng Zhanhe Pan Shusen Wang Tongyu Lin Wenqi Jiang Zhongzhen Guan | 2006 | The Chinese-German Journal of Clinical Oncology2006，5，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员